Eli Lilly’s triple-G obesity readout; The latest Endpoints 100 results; Public biotechs cash in; and morenews2025-12-13T11:00:18+00:00December 13th, 2025|Endpoints News|
340B sales grew 23% last year, and court battle over pilot program intensifies news2025-12-12T20:47:51+00:00December 12th, 2025|Endpoints News|
Covid vaccine deaths review sent to top of FDA, but with far less certain conclusions, sources saynews2025-12-12T20:36:22+00:00December 12th, 2025|Endpoints News|
A 2-speed payer transformation is underwaynews2025-12-12T17:29:45+00:00December 12th, 2025|Endpoints News|
CHMP calls to reject Anavex’s Alzheimer’s pill over impurities, side effects and weak efficacynews2025-12-12T17:27:18+00:00December 12th, 2025|Endpoints News|
#SABCS25: Celcuity further details Phase 3 win; Relay’s PI3Kα inhibitor’s consistent performance; and morenews2025-12-12T16:20:58+00:00December 12th, 2025|Endpoints News|
Arcus, Gilead report Phase 3 TIGIT failure in upper GI cancersnews2025-12-12T15:59:53+00:00December 12th, 2025|Endpoints News|
Innovent’s obesity drug data in adolescents; Everest gets rights to PCSK9 inhibitornews2025-12-12T14:36:09+00:00December 12th, 2025|Endpoints News|
GSK spins out corporate VC fund focused on bioelectronic technews2025-12-12T14:11:50+00:00December 12th, 2025|Endpoints News|
Tenaya targets $60M offering after heart disease pipeline updatesnews2025-12-12T12:04:38+00:00December 12th, 2025|Endpoints News|
